JLJiaye Liu

Jiaye Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jiaye Liu has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Yinyun Ni

    Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease‐related Molecular Network, Center of Precision Medicine, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital Sichuan University Chengdu China

    3 shared publications
  • Zhihui Li

    Division of Thyroid Surgery, Department of General Surgery, Laboratory of Thyroid and Parathyroid Diseases, Frontiers Science Center for Disease‐Related Molecular Network, West China Hospital Sichuan University Chengdu China

    3 shared publications
  • Chunyang Mu

    Department of Liver Surgery & Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China

    2 shared publications
  • Junyi Shen

    Department of Liver Surgery & Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China

    2 shared publications
  • Wenshuang Wu

    Department of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University, Chengdu, China

    2 shared publications
  • Yang Liu

    Department of Obstetrics and Gynecology, The Second Affiliated Hospital Chongqing Medical University Chongqing China

    2 shared publications

Latest Publications

  • Global Annualized Recurrence Rates and Dynamic Risk Profiles in Head and Neck Cancer

    by Yiqiao Fang, Cheng Yi, Ruonan Sun, Bingbing Shen, Menglin Yao, Ying Yang, Yinyun Ni, Yang Liu, Zhihui Li, Jiaye Liu

    Recurrence limits survival in head and neck cancer (HNC), yet its annualized rate remains poorly defined due to heterogeneous follow‐up durations across studies. In this systematic review and meta‐analysis, we searched four databases from inception to May 1, 2025, and included 1060 studies comprising 336,615 patients and 1.40 million person‐years of follow‐up. Using person‐time analysis, we estimated a global recurrence rate of 6.57 per 100 person‐years (95% CI, 6.28–6.87). Recurrence rates varied substantially across settings, with higher rates observed in lower‐middle‐income countries (10.16 per 100 person‐years) and in hypopharyngeal cancers (14.11 per 100 person‐years). Median follow‐up duration explained the largest share of between‐study heterogeneity ( R 2 = 37.12%), and studies with shorter reported follow‐up tended to show higher annualized recurrence rates. Substantial differences in recurrence rates were noted when stratified by clinical and biological factors. Notably, the prognostic impact of patient age and tumor stage was time‐dependent, being most pronounced in the early post‐treatment period and attenuating over time. Patients with recurrent disease faced a high mortality risk, with a pooled case fatality rate of 55.80% (95% CI, 51.20–60.30). These findings quantify a high global recurrence rate of HNC with pronounced time dependence, informing risk‐adapted surveillance strategies and early, histology‐specific prevention to reduce recurrence‐related mortality.


  • Open Access

    Pancreatic tumor eradication via selective Pin1 inhibition in cancer-associated fibroblasts and T lymphocytes engagement

    by Jiaye Liu, Yang Wang, Chunyang Mu, Meng Li, Kewei Li, Shan Li, Wenshuang Wu, Lingyao Du, Xiaoyun Zhang, Chuan Li, et al.

    Cancer associated fibroblasts (CAFs) support tumors via multiple mechanisms, including maintaining the immunosuppressive tumor microenvironment and limiting infiltration of immune cells. The prolyl isomerase Pin1, whose overexpression in CAFs has not been fully profiled yet, plays critical roles in tumor initiation and progression. To decipher effects of selective Pin1 inhibition in CAFs on pancreatic cancer, here we formulate a DNA-barcoded micellular system (DMS) encapsulating the Pin1 inhibitor AG17724. DMS functionalized with CAF-targeting anti-FAP-α antibodies (antiCAFs-DMS) can selectively inhibit Pin1 in CAFs, leading to efficacious but transient tumor growth inhibition. We further integrate DNA aptamers (AptT), which can engage CD8+ T lymphocytes, to obtain a bispecific antiCAFs-DMS-AptT system. AntiCAFs-DMS-AptT inhibits tumor growth in subcutaneous and orthotopic pancreatic cancer models.


  • Open Access

    Recapitulating hepatitis E virus–host interactions and facilitating antiviral drug discovery in human liver–derived organoids

    by Pengfei Li, Yunlong Li, Yijin Wang, Jiaye Liu, Marla Lavrijsen, Yang Li, Ruyi Zhang, Monique M. A. Verstegen, Yining Wang, Tian-Cheng Li, et al.

    Hepatotropic viruses naturally have narrow host and tissue tropisms, challenging the development of robust experimental models. The advent of organoid technology provides a unique opportunity for moving the field forward. Here, we demonstrate that three-dimensional cultured organoids from fetal and adult human liver with cholangiocyte or hepatocyte phenotype support hepatitis E virus (HEV) replication. Inoculation with infectious HEV particles demonstrates that human liver–derived organoids support the full life cycle of HEV infection. By directing organoids toward polarized monolayers in a transwell system, we observed predominantly apical secretion of HEV particles. Genome-wide transcriptomic and tRNAome analyses revealed robust host responses triggered by viral replication. Drug screening in organoids identified brequinar and homoharringtonine as potent HEV inhibitors, which are also effective against the ribavirin resistance variant harboring G1634R mutation. Thus, successful recapitulation of HEV infection in liver-derived organoids shall facilitate the study of virus-host interactions and development of antiviral therapies.


  • Open Access

    High‐dose vitamin D metabolite delivery inhibits breast cancer metastasis

    by Jiaye Liu, Junyi Shen, Chunyang Mu, Yang Liu, Dongsheng He, Han Luo, Wenshuang Wu, Xun Zheng, Yi Liu, Sunrui Chen, et al.

    Besides its well‐known benefits on human health, calcitriol, the hormonally active form of vitamin D3, has been being evaluated in clinical trials as an anticancer agent. However, currently available results are contradictory and not fundamentally deciphered. To the best of our knowledge, hypercalcemia caused by high‐dose calcitriol administration and its low bioavailability limit its anticancer investigations and translations. Here, we show that the one‐step self‐assembly of calcitriol and amphiphilic cholesterol‐based conjugates leads to the formation of a stable minimalist micellar nanosystem. When administered to mice, this nanosystem demonstrates high calcitriol doses in breast tumor cells, significant tumor growth inhibition and antimetastasis capability, as well as good biocompatibility. We further reveal that the underlying molecular antimetastatic mechanisms involve downregulation of proteins facilitating metastasis and upregulation of paxillin, the key protein of focal adhesion, in primary tumors.